Search Results Search Sort by RelevanceMost Recent Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 2 Sonya Charles, PhD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):379-383. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Health Law Jul 2019 Who Makes Decisions for Incapacitated Patients Who Have No Surrogate or Advance Directive? Scott J. Schweikart, JD, MBE Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative. AMA J Ethics. 2019;21(7):E587-593. doi: 10.1001/amajethics.2019.587. Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.
Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 2 Sonya Charles, PhD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):379-383. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Health Law Jul 2019 Who Makes Decisions for Incapacitated Patients Who Have No Surrogate or Advance Directive? Scott J. Schweikart, JD, MBE Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative. AMA J Ethics. 2019;21(7):E587-593. doi: 10.1001/amajethics.2019.587.